Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 20 Mar
    2017

    Interim Results for the six months ended 31 December 2016

    On track to becoming a world leading specialty pharma company in endocrinology

    Read More

  • 16 Mar
    2017

    Diurnal appoints Clinigen to launch a European Patient Access programme for Infacort® and Chronocort®

    Infrastructure and supply chain now in place to provide Infacort® and Chronocort® as unlicensed medicines to patients on a Named Patient basis

    Read More

  • 02 Mar
    2017

    Diurnal signs marketing and distribution agreement for the commercialisation of Infacort® and Chronocort® in Israel

    The agreement covers the commercialisation in Israel of Diurnal’s novel therapies for adrenal insufficiency, Infacort® and Chronocort®.

    Read More